UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 -------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2002 Commission File Number: 000-31255 ISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0511729 -------- ---------- (State of incorporation or organization) (IRS Employer I.D. No.) 15279 Alton Parkway, Suite 100 Irvine, CA 92618 ---------------- (Address of principal executive offices) (949) 788-6000 -------------- (Registrant's telephone number, including area code) ITEM 5. OTHER EVENTS On January 2, 2002, ISTA Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Board of Directors of the Company had approved the adoption of a Preferred Stock Rights Agreement. The press release is attached as Exhibit 99 to this Form 8-K ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits. Exhibit 99 ISTA Pharmaceuticals, Inc. Press Release issued January 2, 2002. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the report to be signed on its behalf by the undersigned thereunto duly authorized. ISTA PHARMACEUTICALS, INC. By /s/ J.C. MacRae --------------------------- J.C. MacRae Executive Vice President, Chief Operating Officer and Chief Financial Officer Dated: January 2, 2002 INDEX TO EXHIBITS Exhibit No. Description - ----------- ----------- 99 ISTA Pharmaceuticals, Inc. Press Release issued January 2, 2002.